Contact

EVŌQ MedTech is a development-stage nanotech innovator bringing a breakthrough antimicrobial platform to the medical device industry.
By incorporating antimicrobial protection into the material manufacturing process, our technology enables the next generation of medical devices to be intrinsically equipped with safeguards against pathogenic microorganisms like bacteria and fungi.

OUR SCIENCE

We have developed the first and only non-ionic silver nanoparticle, EVQ-218. Extensive lab studies demonstrate that EVQ-218 delivers high antimicrobial efficacy without ionic emissions, opening possibilities for widespread therapeutic use.1,2

NOVEL MECHANISM OF ACTION

The antimicrobial efficacy of EVQ-218 is rooted in its ability to disrupt bacteria’s metabolic processes.

  • By sequestering sulfur, EVQ-218 stops bacterial growth without compromising cell structures.
  • This disruption process leads to cell death without initiating drug resistance.
  • In contrast, ionic silver nanoparticles initiate drug resistance when rupturing cell walls.

Antimicrobial Platform Boasts Several Distinct Attributes:

  • Uniform Sub-10nm: Enables effective cell interaction and offers a high surface-area-to-volume ratio with repeatable results.
  • Non-Ionic: Efficacy without the risks and limitations linked to ion emissions.
  • Non-Oxidative: Mitigates need for added stabilizers and surface coatings.
  • Non-Toxic/Environmentally Friendly: No toxic byproducts created in the manufacturing process.

View Fact Sheet

PROVEN ANTIMICROBIAL EFFICACY

Validated lab testing of catheters, luers, and fittings manufactured with our proprietary antimicrobial nanoparticles extruded throughout the polymer demonstrated:

  • Strong antifungal and antibiofilm efficacy.
    • 4+ log reduction
  • Broad spectrum activity against all bacterial strains tested.
    • 64 strains
  • No degradation of antimicrobial activity; sustained presence for the life of the product.

COMBATING HEALTHCARE-ASSOCIATED INFECTIONS (HAI)

Our antimicrobial nanoplatform is well positioned to target the 1 million+ Healthcare-Associated Infections (HAIs) that occur across the U.S. health care system annually, estimated to cost billions of dollars per year. 3

Bloodstream, pulmonary and urinary tract infections are a significant cause of morbidity and increased mortality in health systems across the U.S. and globally.4 In the U.S. alone, there are 250,000 central line associated bloodstream infections (CLABSI) every year5 from central-venous (CVC), subclavian (SC), internal jugular (IJ) and femoral (FEM) catheters.6

One million catheter-associated urinary tract infections (CAUTI) occur annually in the U.S. and 24-33% are drug resistant.7 Standard practice for hospitals and health systems is to remove/replace catheters at 15 days because data shows that nearly 100% of patients with catheters for more than 28 days will develop dangerous infections and are at risk for sepsis.

Current antibacterial coated catheters lose efficacy once inserted into patients, due to natural sloughing of the material, coupled with the short life of silver ion emission hindering the antimicrobial activity of the coatings. By embedding EVŌQ MedTech’s nanoparticles directly into the catheter, leading manufacturers aim to harness the precision and potency of our multi-patented platform to combat drug-resistant bacteria and significantly reduce HAI incidence.

References

  1. Dimpka, C.O. Calder, A. Gajjar, P. Merugu, S. Huang, W. Britt, D.W. McLean, J.E. Johnson, W.P. Anderson, A.J. Interaction of silver nanoparticles with an environmentally beneficial bacterium, Pseudomonas chlororaphis. J. Haz. Mat. 2011; 188:428-435. DOI: 10.1016/j.jhazmat.2011.01.118
  2. Niedermeyer, W. Method and apparatus for production of uniformly sized nanoparticles. US 9 849 512, 2017.
  3. Patient Safety Network. Health Care-Associated Infections, September 7, 2019. Accessed 21 Nov 2023.
  4. Al-Rawajfah OM, Hewitt JB, Stetzer F, Cheema J. Length of stay and charges associated with health careacquired bloodstream infections. Am J Infect Control. 2012;40:227–32.
  5. O’Grady NP, Alexander M, Dellinger EP, Burns LA, Garland J, Heard SO, et al. Guidelines for the prevention of intravascular catheter-related infections. Atlanta: Centers for Disease Control and Prevention; 2011.
  6. Pitiriga, Kanellopoulos, P., Bakalis, I. et al. Central venous catheter-related bloodstream infection and colonization: the impact of insertion site and distribution of multidrug-resistant pathogens. Antimicrob Resist Infect Control 9, 189 (2020). https://doi.org/10.1186/s13756-020-00851-1
  7. Köves B, Magyar A, Tenke P. Spectrum and antibiotic resistance of catheter-associated urinary tract infections. GMS Infect Dis. 2017 Nov 22;5:Doc06. doi: 10.3205/id000032. PMID: 30671328; PMCID: PMC6301742.

Contact Us

Interested in learning more or partnering with us? Let’s connect!

1895 W 2100 S
Suite 100
Salt Lake City, UT 84119